Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: James Perry who wrote (452)	10/4/1998 11:55:00 AM
From: LPasko	Respond to of 1025

Thank you for that thoughtful and thorough reply. It is much appreciated.

To: James Perry who wrote (452)	10/5/1998 5:42:00 PM
From: Invest2Ride	Read Replies (3) \| Respond to of 1025

The royalties from the device constitute a payoff of a single patent, no matter what the settlement with Roche is. IGEN's potential stems from the reality that owning a device is not enough for most POC sales. The real value comes from developing the TESTS THAT USE THE DEVICE!!! Each test is its own patent and royalty income generating unit. Applying biological terminology to the business situation -- it's a positive autocrine feedback loop! As long as IGEN keeps churning out applications for their technology and retaining the rights to them, it's a potential goldmine. The drug companies want the machines to more quickly identify new products -- guess what -- the resulting tests for those genes will utilize the POC version of IGEN's machine. POC will be the thing to control from IGEN's perspective, which is why they retained those rights in the first place.